ExLibris header image
SFX Logo
Title: Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study
Source:

Pharmaceutical Research [0724-8741] Nounou, Mohamed yr:2016


Collapse list of basic services Basic
Full text
Full text available via SpringerLINK Contemporary 1997-Present
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Lammers P., P. "Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: A physician survey in the united states and emerging markets." Pharmaceuticals 7.9 (2014): 943-953. Link to Full Text for this item Link to SFX for this item
2. Kulkarni, DG G. "HER2+breast cancer." American journal of clinical pathology 129.2 (2008): 263-273. Link to SFX for this item
3. Liao, Y. "Abstract 403: The role of HER2 in the brain metastatic cascade in breast cancer." Cancer research 73.8 Supplement (2013): 403-403. Link to SFX for this item
4. Osborne, Rachel K. "Targeting HER2 for the Treatment of Breast Cancer." Annual Review of Medicine 66.1 (2015): 111-28. Link to Full Text for this item Link to SFX for this item
5. Kulka, C. "Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study." Annals of Oncology 18.12 (2008): 1963-8. Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.